Journal profile · Endocrinology & Metabolism
Diabetes Research and Clinical Practice
ISSN 0168-8227 · eISSN 1872-8227 · Elsevier Ireland Ltd · NETHERLANDS · Monthly
Diabetes Research and Clinical Practice: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.51; hybrid open access; APC about USD 4,410; median 59 days to acceptance (119 articles, last 24 months); community-reported acceptance: about 50%; 1,008 articles in 2025; indexed in SCIE and Scopus.
The journal's website announces a move to full open access: At Elsevier, we are committed to advancing human progress and making research accessible to everyone. We are pleased to announce that from January 1, 2027, Diabetes Research and Clinical Practice will become a fully open access journal, with all articles freely available to readers worldwide. Source ↗Publisher website ·
Scope
Aims, scope and focus
Diabetes Research and Clinical Practice is published by Elsevier Ireland Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins and Diabetes Treatment and Management, together about 36% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas.The role Diabetes Research and Clinical Practice is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care.The journal publishes topics including:translational sciencegeneticsimmunologynutritionpsychosocial researchepidemiologypreventionsocio-economic researchcomplicationsnew treatmentstechnologiestherapy
From the journal's Aims & Scope
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief A. CerielloPublisher website
Editorial board by country: 4 in mainland China (about 9%); most named Italy 7, India 6, Mainland China 4, Hong Kong, China 3, United Kingdom 3 (47 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Management and ResearchMedicine14%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine12.4%
- Diabetes Treatment and ManagementMedicine9.6%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology8.5%
- Diabetes Management and EducationMedicine7.5%
- Pancreatic function and diabetesMedicine6%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology4.2%
- Hyperglycemia and glycemic control in critically ill and hospitalized patientsMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.51LetPub ·
- Impact factor (publisher)
- 4.6Publisher website ·
- CiteScore 2026-06
- 12.6LetPub ·
- CiteScore (publisher)
- 12.6Publisher website ·
- SJR 2026-06
- 1.69LetPub ·
- SNIP 2026-06
- 2.39LetPub ·
- h-index
- 100LetPub ·
- h-index
- 183OpenAlex ·
- i10-index
- 6,470OpenAlex ·
- 2-year mean citedness
- 2.74OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 24.57%LetPub ·
Volume
- Articles per year
- 508LetPub ·
Articles by year OpenAlex count · 16,302 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 423 | 160 | 206 |
| 2025 | 1,008 | 539 | 2,824 |
| 2024 | 806 | 185 | 3,105 |
| 2023 | 718 | 256 | 5,517 |
| 2022 | 904 | 630 | 7,204 |
| 2021 | 415 | 164 | 21,227 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
59 daysMedian, submission to acceptance · P25–P75 35 days – 91 days
- Acceptance to online
- median 2 days (119 articles)
- Submission to online
- median 64 days
- Sample
- 119 articles with submission and acceptance dates (1,098 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 34 daysPublisher website ·
- Submission to acceptance
- 79 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,410 / EUR 4,130 / GBP 3,530 / JPY 546,970 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- ≥ 1
- Manuscript length
- ≤ 5,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
Article types accepted9, with length limits
- commentariesCommentaries (1000 words not including a maximum of 20 references and one small figure) offer a stimulating, journalistic and accessible insight into issues of …Length not stated
- commentaryces; one small figure can be included). Commentaries Commentaries (1000 words not including a maximum of 20 references and one small figumain text ≤ 1,000 words · references ≤ 20
- editorial(below) will be declined automatically. Editorials Written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 refere…main text ≤ 1,000 words · references ≤ 20
- editorialsEditorials Written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 references; one small figure can be included).Length not stated
- letters to the editorThese should be no more than 400 words. Note Brief Reports and Letters to the Editor will only be published electronically but will be listed in the print Table…main text ≤ 400 words
- research articlesResearch Articles should be designated either (a) Basic Research (b) Clinical Research or (c) Epidemiology and should be a maximum of 5000 words.Length not stated
- research briefsResearch Briefs These should not exceed 1000 words, including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminar…Length not stated
- review articleation not requiring a lengthy write-up. Review articles These should be a maximum of 5000 words, including a summary of no more than 200 words (not includimain text ≤ 5,000 words · references ≤ 75
- review articlesReview articles These should be a maximum of 5000 words, including a summary of no more than 200 words (not including up to 75 references) with subheadings in t…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Ireland Ltd
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Monthly
- ISSN
- 0168-8227
- Electronic ISSN
- 1872-8227
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Diabetes Research and Clinical Practice
What CAS zone is Diabetes Research and Clinical Practice in?
In the 2025 upgraded edition of the CAS Journal Ranking, Diabetes Research and Clinical Practice is in Zone 3 of Medicine, and in Zone 3 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Diabetes Research and Clinical Practice?
The latest impact factor listed by LetPub is 4.51; CiteScore 12.6, h-index 183.
How long does peer review take at Diabetes Research and Clinical Practice?
Based on the dates recorded on 119 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 59 days (interquartile range 35–91 days); authors report an average review time of about 4 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Diabetes Research and Clinical Practice?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: ≥ 1; Manuscript length: ≤ 5,000 words; Reference style: Numbered, in order of citation; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Diabetes Research and Clinical Practice based?
Of the 47 board members whose country the journal's board page names, 4 (about 9%) are in mainland China; the countries named most often are Italy (7), India (6) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Diabetes Research and Clinical Practice?
According to LetPub and DOAJ records, Diabetes Research and Clinical Practice is indexed in SCIE and Scopus.
Is Diabetes Research and Clinical Practice open access, and what is the APC?
Diabetes Research and Clinical Practice is a hybrid journal. For open-access publication: APC about USD 4,410.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .